Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Partners With Aussie Hospital on Precision Medicine Pilot Study

NEW YORK – Molecular diagnostics firm Genetic Technologies on Wednesday said it is working with Gold Coast Private Hospital (GCPH) in Australia to set up the framework for a precision medicine clinic.

GCPH, which is part of Australia's private hospital network Healthscope, is partnering with Genetic Technologies to conduct a pilot study, within which 50 patients will be genomically profiled to gauge their risks for various diseases and characterize their response to medications. Researchers will use Genetic Technologies' pharmacogenomics tests and GeneType Multi-risk assay, which gauges patients' predisposition for coronary artery disease, type 2 diabetes, and breast, colorectal, ovarian, and prostate cancers.

The insights from this trial, which GCPH plans to begin enrolling immediately, will inform clinical workflows and how test results should be reported at the precision medicine clinic. "We have a clear vision for a Precision Medicine Clinic that focuses on preventative care, wellness, and creating proactive patient pathways that lead to early detection and better treatment of the common diseases," Michelle Ferrari Cestari, research manager at GCPH, said in a statement.

According to Melbourne, Australia-based Genetic Technologies, if its genetic tests allow doctors to personalize care for their patients leading to improved outcomes in the pilot study, then it could spur Healthscope to roll out other precision medicine clinics within its network of 42 hospitals throughout Australia.